January 16, 2018 / 6:21 AM / a month ago

BRIEF-Novartis says data reinforces ‍Cosentyx effectiveness

Jan 16 (Reuters) - Novartis AG:

* NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS

* ‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​

* ‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​ Source text for Eikon: Further company coverage: (Reporting By Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below